Bromodomain inhibitors for cancer therapy

Abstract

The present disclosure relates to PFI-3-derived bromodomain inhibitor compounds and their use in treating glioblastoma and other cancers. New small-molecule analogs organized into compound series 2, 3, 4 and 5 selectively target BRG1/BRM bromodomains and sensitize glioblastoma cells to DNA-alkylating agents such as temozolomide. The compounds, their pharmaceutically acceptable salts and prodrugs are provided, together with pharmaceutical compositions comprising at least one such compound optionally in combination with a DNA-alkylating agent. Methods of treating cancer, including temozolomide-resistant glioblastoma, by administering a therapeutically effective amount of at least one of the disclosed compounds alone or in combination with temozolomide are also described.

Dependencies are inferred from the claim text.